1. Home
  2. AYI vs TGTX Comparison

AYI vs TGTX Comparison

Compare AYI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acuity Brands Inc.

AYI

Acuity Brands Inc.

HOLD

Current Price

$306.06

Market Cap

9.6B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$56.00

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AYI
TGTX
Founded
2001
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
8.5B
IPO Year
2001
2008

Fundamental Metrics

Financial Performance
Metric
AYI
TGTX
Price
$306.06
$56.00
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$369.17
$49.80
AVG Volume (30 Days)
206.2K
1.5M
Earning Date
04-02-2026
05-04-2026
Dividend Yield
0.28%
N/A
EPS Growth
N/A
1746.67
EPS
11.45
0.17
Revenue
$3,461,000,000.00
$2,785,000.00
Revenue This Year
$7.51
$49.08
Revenue Next Year
$5.14
$26.69
P/E Ratio
$27.14
$341.82
Revenue Growth
4.05
N/A
52 Week Low
$257.04
$26.76
52 Week High
$380.17
$59.30

Technical Indicators

Market Signals
Indicator
AYI
TGTX
Relative Strength Index (RSI) N/A 61.78
Support Level N/A $51.76
Resistance Level N/A $58.12
Average True Range (ATR) 0.00 2.02
MACD 0.00 0.21
Stochastic Oscillator 0.00 84.03

Price Performance

Historical Comparison
AYI
TGTX

About AYI Acuity Brands Inc.

Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. It designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: